Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $92.60.

PBH has been the subject of several analyst reports. DA Davidson lifted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Canaccord Genuity Group lifted their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Oppenheimer lifted their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Finally, Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $84,932,000. Vise Technologies Inc. acquired a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $319,000. McIlrath & Eck LLC increased its position in Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after acquiring an additional 154 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Prestige Consumer Healthcare by 24.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 118,113 shares of the company’s stock worth $9,223,000 after buying an additional 23,334 shares during the period. Finally, Vident Advisory LLC grew its position in shares of Prestige Consumer Healthcare by 2.8% during the 4th quarter. Vident Advisory LLC now owns 11,254 shares of the company’s stock worth $879,000 after buying an additional 305 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

NYSE:PBH opened at $84.66 on Friday. The company has a 50-day moving average of $79.42 and a 200-day moving average of $76.38. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 2.69 and a beta of 0.50. Prestige Consumer Healthcare has a 52 week low of $62.35 and a 52 week high of $88.36. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, equities research analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.